Some doctors got worse at detecting cancer after relying on AI
The researchers set out to discover whether continuous exposure to AI impacted doctors' behavior when conducting colonoscopy, so they decided to assess 'how endoscopists who regularly used AI performed colonoscopy when AI was not in use.'
The answer: Not so hot. The rate was about six percentage points lower.
The study was published in The Lancet Gastroenterology & Hepatology journal by medical professionals and researchers in countries including Poland, Norway, Sweden, the U.K., and Japan. It followed doctors at four endoscopy centers in Poland, which were part of a trial program focusing on AI's use in colonoscopy for potential cancer prevention.
It raises questions about the use of AI in healthcare, when it helps and when it could hurt. Last week, The Verge reported on a Google healthcare AI model's instance of potentially hallucinating a body part and where medical professionals think the industry will go from here.Posts from this author will be added to your daily email digest and your homepage feed.
See All by Hayden Field
Posts from this topic will be added to your daily email digest and your homepage feed.
See All AI
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Health
Posts from this topic will be added to your daily email digest and your homepage feed.
See All News
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Science
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Drug that slows onset of type 1 diabetes licensed for use in UK-first
A groundbreaking drug that slows down the development of type 1 diabetes has been licensed for use in the UK. Teplizumab can allow patients to live 'normal lives' without the need for insulin injections. Experts hailed the decision by the Medicines and Healthcare Regulatory Agency (MHRA) as a 'breakthrough moment' that represents a 'turning point' in how the condition is treated. About 400,000 people in the UK have type 1 diabetes, a lifelong condition which causes the immune system to attack insulin-producing cells in the pancreas. Insulin helps the body use sugar for energy, and without this hormone, blood sugar levels can become dangerously high. Type 1 diabetes needs constant management to keep blood sugar within range, with patients required to take insulin through injections or pumps. Teplizumab trains the immune system to stop attacking pancreatic cells. It is taken by an IV drip for a minimum of 30 minutes over 14 consecutive days. The drug, which is already approved in the US, has been authorised for use by the MHRA to delay the onset of stage three type 1 diabetes in adults and children aged eight or over by an average of three years. Ahmed Moussa, general manager of general medicines UK and Ireland at Sanofi, which makes teplizumab, said: 'One hundred years ago the discovery of insulin revolutionised diabetes care. Today's news marks a big step forward.' The UK is the first country in Europe to be granted a licence. Type 1 diabetes develops gradually in three stages over months or years. Stage three is usually when people start to experience blood sugar problems and are diagnosed with the condition. According to the MHRA, teplizumab is used in people with stage two type 1 diabetes, which is an earlier stage of the disease during which patients are at a high risk of progressing to stage three. Parth Narendran, a professor of diabetes medicine at the University of Birmingham and The Queen Elizabeth Hospital Birmingham, said: 'Teplizumab essentially trains the immune system to stop attacking the beta cells in the pancreas, allowing the pancreas to produce insulin without interference. 'This can allow eligible patients to live normal lives, delaying the need for insulin injections and the full weight of the disease's daily management by up to three years. It allows people to prepare for disease progression rather than facing an abrupt emergency presentation.' Following the decision by the MHRA, the cost-effectiveness of teplizumab will be assessed by NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to determine if it can be rolled out on the health service. Karen Addington, chief executive of the charity Breakthrough T1D, said: 'I am personally delighted and welcome the MHRA's approval of teplizumab. 'After years of research, clinical trials and drug development, we have an incredible breakthrough.' Reacting to the announcement, Dr Elizabeth Robertson, director of research and clinical at Diabetes UK, said: 'Today's landmark licensing of teplizumab in the UK marks a turning point in the treatment of type 1 diabetes. 'For the first time, we have a medicine that targets the root cause of the condition, offering three precious extra years free from the relentless demands of managing type 1 diabetes.' Dr Robertson added that the 'next steps are critical'. 'To ensure teplizumab reaches everyone who could benefit, we need it to be made available on the NHS, and the rollout of a screening programme to identify those with early-stage type 1 diabetes,' she said.
Yahoo
24 minutes ago
- Yahoo
Inquiry into rogue surgeon to hold preliminary hearing next month
A public inquiry set up to investigate disgraced surgeon Sam Eljamel will hold a preliminary hearing next month. The Eljamel Inquiry will investigate the activities and oversight of Mr Eljamel, who was appointed by NHS Tayside as a consultant neurosurgeon at Ninewells Hospital in Dundee in 1995 and went on to become head of neurosurgery at the site. In 2013, Mr Eljamel was placed under supervision and later suspended following concerns about the standard of clinical care he was providing to patients. He resigned from NHS Tayside in 2014. Patients of the former neurosurgeon have claimed he harmed as many as 200 people, with some suffering life-changing injuries. The Eljamel Inquiry will determine, among other things, whether patients were let down by failures in clinical governance, risk management, and complaints procedures, and the adequacy of previous reviews. It will also examine to what extent Mr Eljamel's private practice, research, and workload impacted on care received by his patients, and whether, and if so to what extent, Mr Eljamel and NHS Tayside tried to conceal evidence of sub-standard care. The independent public inquiry, chaired by Lord Weir, will hold a preliminary hearing in Edinburgh on September 10 to set out its progress and intentions. Scotland's Health Secretary Neil Gray formally set up the inquiry on April 3, empowering it to begin the process of gathering evidence. To date, Lord Weir has designated applicants including NHS Tayside, 133 former patients of Mr Eljamel and 19 personal representatives of former patients. This group is represented by the legal firm Levy & McRae. The Scottish Government and the University of Dundee are also designated as core participants, as are the Royal College of Surgeons (Edinburgh), Healthcare Improvement Scotland, and NHS Education for Scotland. Members of the public, including former patients, can apply to attend the preliminary hearing in person. Proceedings will also be broadcast live on the inquiry's YouTube channel, and will be available to view later on its website. The preliminary hearing will take place at Waverley Gate in central Edinburgh.
Business Wire
25 minutes ago
- Business Wire
Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Philips, a global leader in health technology, today announced a plan for new investments of more than USD 150 million in U.S. manufacturing and research and development (R&D). As part of today's announcement, Philips unveiled the expansion of its Reedsville, PA, manufacturing facility, which produces AI-enabled ultrasound systems for hospitals across the U.S. These investments come on top of Philips' annual USD 900 million R&D investment in the U.S. as well as investments in nearly 17,000 colleagues across 40 facilities in the United States. Philips has employees in every U.S. state supporting innovations used by clinicians and patients in 90% of hospitals across the country. The investment announced today by Philips includes the expansion of its Reedsville, PA, site and the recently announced expansion of Philips' Image Guided Therapy facility in Plymouth, MN. It also includes additional manufacturing and R&D projects which will come over the next several years to support the company's growth in the U.S. The Reedsville site, which currently manufactures transducers, will also customize the software and configurations of ultrasound systems for specific clinical procedures in cardiovascular, general and maternal care following the expansion. As an example, Philips' industry-leading CV ultrasound platform delivers advanced tools to help doctors diagnose structural heart and coronary artery disease quickly and confidently [1]. 'The proposed planned expansion of our manufacturing facilities is a demonstration of our deep commitment to the U.S. region,' said Jeff DiLullo, Chief Region Leader, Philips North America. 'Each year, Philips spends $900 million in R&D in the U.S. to drive innovation and deliver cutting-edge technology that empowers healthcare professionals to diagnose, treat and monitor patients more effectively. Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.' The expansion of the Reedsville site is expected to add 24,000 square feet of manufacturing space in addition to 40,000 square feet of warehouse space and is expected to create 120 skilled manufacturing jobs. The recently announced expansion of Philips' image-guided therapy facility in Plymouth, MN, which includes the construction of a new medtech training center, is expected to create over 150 new jobs. [1] Philips ultrasound: The next dimension in echocardiography About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at Forward-looking statements and other important information This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
